Cereno Scientific (CRNO) CMD 2026 summary

Strategic focus and business development

• Advancing CS1 into a global phase IIb trial for pulmonary arterial hypertension (PAH), with first patient in Q2 2026 and top-line data expected in Q4 2028, aiming for disease modification and remission rather than symptom management.

• CS014's development shifted from IPF to pulmonary hypertension with interstitial lung disease (PH-ILD) to optimize market entry, cost, and probability of success, with IND submission planned for this year.

• Strategic partnering, co-development, out-licensing, and potential M&A are prioritized, with ongoing discussions at global, regional, and local levels to maximize asset value.

• Expanding the investor base and closing a major pharma partnership are key near-term objectives.

• Biotech innovation is highlighted as the main driver for new drug development, with pharma primarily launching rather than innovating, reinforcing the importance of strategic partnerships.

Clinical progress and trial design

• CS1 is advancing to a global, double-blind, randomized, placebo-controlled phase IIb trial in PAH across 10-12 countries, with all participants receiving active treatment at some point.

• The trial is designed for disease modification, featuring a 9-month primary endpoint (pulmonary vascular resistance), medication withdrawal period, and comprehensive secondary endpoints including quality of life and functional assessments.

• Fast-track and orphan drug designations from FDA and EMA provide regulatory advantages and closer authority interaction, with ongoing preparations for EMA and South American approvals.

• Expanded access program and phase IIa data show promising safety, tolerability, and early efficacy signals, including improvements in right heart function and quality of life.

• The HDACI platform includes two clinical-stage programs (CS1, CS014) and one preclinical program (CS585 for rare thrombotic disorders), supported by a world-class steering committee and CRO.

Market opportunity and value proposition

• The global PAH/PH market is projected to reach $13 billion by 2031/2032, with CS1 expected to capture a significant share due to its oral, once-daily, well-tolerated profile and potential for early use in the treatment algorithm.

• Analyst-estimated deal value for CS1 after a successful phase IIb is around $2 billion, with peak sales potential estimated at $2–4 billion annually; CS014 in PH-ILD is estimated to have a $2-4B market potential.

• Disease modification and remission are positioned as key differentiators, with the potential to expand into additional indications and create a broader franchise.

• The company’s rare disease focus leverages orphan drug incentives, premium pricing, and faster, less capital-intensive development.

• Analyst and management estimates for CS1 and CS014 suggest multi-billion dollar peak sales, with additional upside from platform expansion into other rare and thrombotic disorders.